Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;13(17):e70161.
doi: 10.1002/cam4.70161.

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia

Xiaoxia Wu  1   2 , Shenqi Lu  1   2 , Xinhui Zhang  1   2 , Zhen Yang  1   2 , Aining Sun  1   2 , Depei Wu  1   2 , Huifen Zhou  1   2 , Miao Miao  1   2
Affiliations

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia

Xiaoxia Wu et al. Cancer Med. 2024 Sep.

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy-free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph-like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front-line treatment of patients with Ph + ALL.

Keywords: Blinatumomab; Philadelphia chromosome‐positive acute lymphoblastic leukemia; Philadelphia chromosome–like acute lymphoblastic leukemia; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests.

References

    1. Jabbour E, Short NJ, Jain N, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16(1):22. - PMC - PubMed
    1. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia following treatment with Blinatumomab: results from a phase II, single‐arm, Multicenter Study. JCO. 2017;35(16):1795‐1802. - PubMed
    1. Foà R, Bassan R, Vitale A, et al. Dasatinib‐Blinatumomab for Ph‐positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613‐1623. - PubMed
    1. Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a US, single‐centre, single‐arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24‐e34. - PubMed
    1. Kantarjian H, Short NJ, Haddad FG, et al. Results of the simultaneous combination of Ponatinib and Blinatumomab in Philadelphia chromosome‐positive ALL. JCO. 2024. - PubMed

MeSH terms

LinkOut - more resources